Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: cis-Capsaicin; Civamide; Civamide 0.075% cream - Winston Pharmaceuticals; Civanex; Civanex Nasal Solution; Dolorac Nasal Solution; Neuroderm Patch; Zuacta

Latest Information Update: 17 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Winston Laboratories
  • Developer Sanofi; Winston Laboratories; Winston Pharmaceuticals
  • Class Catechols; Monounsaturated fatty acids; Polyunsaturated alkamides; Solanaceous alkaloids
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Phase II Keratoconjunctivitis sicca
  • No development reported Cluster headache; Crohn's disease; Migraine; Postherpetic neuralgia; Rhinitis

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 09 Jun 2015 No recent reports on development identified - Phase-II for Crohn's disease in USA (PO, capsule)
  • 09 Jun 2015 No recent reports on development identified - Phase-III for Cluster headache in USA (Intranasal, spray)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top